AC
HTGM

Armistice Capital’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Armistice Capital’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-69,505
Closed -$1.16M – 215
2022
Q1 		$1.16M Buy
+69,505
New +$2.23M 0.02% 105

Other funds holding HTGM

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Armistice Capital's HTGM Position: Q2 2022 in Review

Armistice Capital sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q2 2022, closing a stake of 69,505 shares — an estimated $1.16M sold.

Armistice Capital first reported a position in HTGM in Q1 2022 and held it in 1 quarter. The position peaked at $1.16M in Q1 2022. 21 funds tracked by Wall St. Rank hold HTGM as of Q2 2022.

  • Armistice Capital reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Armistice Capital sold 69,505 HTG Molecular Diagnostics, Inc. Common Stock shares in Q2 2022, an estimated $1.16M.
  • Armistice Capital first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Armistice Capital's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $1.16M in Q1 2022.
  • 21 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q2 2022.

Based on Armistice Capital's 13F filing for Q2 2022, filed 15 Aug 2022.